By revealing significant changes in either abundance or ratios of sn-isomers in a set of GPs during aging and AD progression, we demonstrate that this developed strategy is powerful to uncover potential biomarkers for AD progression associated with dysregulated GP metabolism. This evidence concerns the gene NBEAL2 and Alzheimer disease.